Fig. 7.

Application of PrSC into the pan-cancer cohort and two immunotherapy cohorts.

A. PrSC was significantly associated with the prognosis of patients in 6 cancer types (Log-rank test, p < 0.05).

B. Survival curves showing that the high PrSC score groups had a poorer prognosis than the low score groups in both PD-L1 (left) and PD-1 (right) treatment cohorts (Log-rank test, p < 0.05).

C. Distribution of the PrSC score in different immune phenotypes in the PD-L1 treatment cohort (Kruskal-Wallis test, p < 0.05).

D. Distribution of the PrSC score in different clinical response groups in the PD-L1 treatment cohort (Wilcoxon rank sum test, p < 0.05). SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response.

E. The PrSC score was negatively correlated with TMB in the PD-L1 treatment cohort (Spearman correlation, p < 0.05)

F. The PrSC score was negatively correlated with TNB in the PD-L1 treatment cohort (Spearman correlation, p < 0.05).